Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.

The Journal of clinical endocrinology and metabolism - 1 Aug 2013

Pupilli C, Pinzani P, Salvianti F, Fibbi B, Rossi M, Petrone L, Perigli G, De Feo M L, Vezzosi V, Pazzagli M, Orlando C, Forti G

Abstract excerpt

CONTEXT: Cell-free nucleic acids circulating in plasma are considered a promising noninvasive tool for cancer monitoring. BRAF(V600E) mutation in cell-free DNA (cfDNA) could represent an appropriate marker for papillary thyroid carcinoma (PTC). OBJECTIVE: Our aim is to investigate the role of BRA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Carcinoma, Papillary
Share to DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Proto-Oncogene Proteins B-raf

Share to ROC Curve

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 23788690
DOI: 10.1210/jc.2013-1072

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23788690-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.PMID 23788690Read ↗

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma.Semantic proximity Read ↗

Detection of driver mutations in plasma cell-free nucleic acids in differentiated thyroid neoplasm.Semantic proximity Read ↗

Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.Semantic proximity Read ↗

Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status.Semantic proximity Read ↗

IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?Semantic proximity Read ↗

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.Semantic proximity Read ↗

Circulating Tumor DNA Harboring the BRAFV600E Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients.Semantic proximity Read ↗

Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAFV600E mutation as biomarkers for papillary thyroid carcinoma.Semantic proximity Read ↗

CirculatingBRAFV600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid CarcinomaSemantic proximity Read ↗

Potential of Liquid Biopsy in Papillary Thyroid Carcinoma in Context of miRNA, BRAF and p53 Mutation.Semantic proximity Read ↗

The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.